Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Performance of Lumetry for Arterial Carbon Dioxide (paCO2) Assessment and Chronic Obstructive Pulmonary Disease (COPD) Screening

16 de novembro de 2026 atualizado por: Lumetry Diagnostics GmbH

Evaluation of the Clinical Performance of Lumetry for paCO2 Assessment and COPD Screening

The purpose of this clinical study is to evaluate how well the lumetry device performs in two areas: estimating the level of carbon dioxide in the arterial blood (paCO2) and screening for chronic obstructive pulmonary disease (COPD).

lumetry is a small handheld device that analyzes exhaled breath. Participants breathe normally into the device for 60 seconds. No forced or maximal breathing maneuvers are required for the lumetry measurement.

Today, the carbon dioxide level in the blood is usually measured with a blood gas analysis, which requires a blood sample. COPD is usually diagnosed with spirometry, a lung function test that requires maximal breathing effort and trained staff.

In this study, adults with COPD of different severity and adults without known lung disease each attend a single study visit. All participants perform one lumetry breath measurement and a standard lung function test (forced spirometry). Participants with COPD also give a small capillary blood sample from the earlobe for blood gas analysis, and some of them additionally have their carbon dioxide level measured through the skin (transcutaneous measurement). By comparing the lumetry results with these established methods, the study assesses how accurately the device estimates the carbon dioxide level in the blood. By comparing the lumetry COPD screening result with spirometry and the confirmed clinical diagnosis, the study assesses how reliably the device distinguishes between people with and without COPD.

The study is conducted at one hospital in Vienna, Austria, and will include 300 participants.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

300

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

  • Nome: Nejla Hidic, BSc Biomedical Engineering
  • Número de telefone: +4366488262391
  • E-mail: nejla.hidic@lumetry.at

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 90 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Written informed consent
  • Age between 18 and 90 years
  • Diagnosed chronic obstructive pulmonary disease (COPD), stages GOLD I to IV, or no known lung function pathologies
  • Able to sit upright for the duration of the procedure without exhaustion
  • Women of childbearing potential: not breastfeeding and either a negative pregnancy test prior to the start of the investigation or use of a reliable method of contraception (intrauterine device or oral contraceptive pill) throughout the investigation. Women of childbearing potential are defined as women who have not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and are not postmenopausal (at least 12 months of amenorrhea in a woman over the age of 50 in the absence of other biological or physiological causes).

Exclusion Criteria:

  • Considered by the investigator to be inappropriate for inclusion or unlikely to comply with the requirements of the study
  • Lung disease other than COPD (e.g., asthma); participants with asthma-COPD overlap may be included
  • Previously documented chronic heart failure with an ejection fraction below 40%
  • Mental or physical inability to comply with time schedules and study procedures
  • Current participation in a clinical study that may affect breathing behaviour (medicinal product or medical device), or participation within 30 days prior to screening
  • Prior participation in this clinical investigation
  • Possible or confirmed pregnancy, or breastfeeding

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Diagnóstico
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Participants With and Without COPD

Adults with chronic obstructive pulmonary disease (COPD), stratified by severity (50 GOLD I/II, 50 GOLD III, 50 GOLD IV), and 150 adults without known lung function pathologies. All participants perform a single 60-second lumetry measurement of normal resting breathing, followed by forced spirometry. Participants with COPD additionally undergo arterialized capillary blood gas analysis, with a subgroup of 50 participants with COPD (GOLD III and IV) additionally undergoing transcutaneous carbon dioxide monitoring.

Handheld capnography and spirometry device that estimates the arterial partial pressure of carbon dioxide (paCO2) and provides a COPD screening result from a single 60-second measurement of normal resting breathing. The device also provides the end-tidal carbon dioxide value (petCO2), which serves as comparator for the paCO2 estimate.

Capillary blood sample from the arterialized earlobe, collected immediately after the lumetry measurement. Reference standard for paCO2. Performed in participants with COPD only.

Non-invasive measurement of carbon dioxide through the skin (tcPCO2), recorded as close in time as possible to the lumetry measurement and blood sampling. Comparator for paCO2 estimation. Performed in a subgroup of 50 participants with COPD.

Standard lung function test performed at the end of the study visit in all participants. Together with the documented clinical diagnosis, reference standard for the COPD screening result.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and End-Tidal Carbon Dioxide (petCO2)
Prazo: Day 1 (single study visit)

In participants with chronic obstructive pulmonary disease (COPD), the carbon dioxide level in the arterial blood (paCO2) estimated by lumetry is compared with the value measured in a capillary blood sample (blood gas analysis, reference standard). The average size of the difference, regardless of direction (mean absolute deviation), is calculated for lumetry and for the standard breath-based value (end-tidal carbon dioxide, petCO2). The outcome is the MAD of petCO2 minus the MAD of lumetry, so a positive value means lumetry is closer to the blood gas value.

Day 1 (single study visit)
Sensitivity of the lumetry COPD Screening Result
Prazo: Day 1 (single study visit)

Percentage of participants with COPD, as established by forced spirometry and documented clinical diagnosis (reference standard), who are classified as positive by the lumetry COPD screening result.

Day 1 (single study visit)
Specificity of the lumetry COPD Screening Result
Prazo: Day 1 (single study visit)

Percentage of participants without COPD, as established by forced spirometry and documented clinical diagnosis (reference standard), who are classified as negative by the lumetry COPD screening result.

Day 1 (single study visit)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Standard Deviation of the Differences Between lumetry-Estimated paCO2 and Blood Gas paCO2
Prazo: Day 1 (single study visit)

In participants with chronic obstructive pulmonary disease (COPD), the difference between the lumetry-estimated arterial carbon dioxide level (paCO2) and the paCO2 measured by capillary blood gas analysis (reference standard) is calculated for each participant. The outcome is the standard deviation of these differences, describing the precision of the lumetry estimate. Unit: millimeters of mercury (mmHg).

Day 1 (single study visit)
Percentage of lumetry paCO2 Estimates Within 8 mmHg of Blood Gas paCO2
Prazo: Day 1 (single study visit)

In participants with COPD, the percentage of lumetry paCO2 estimates that differ by 8.0 millimeters of mercury (mmHg) or less in either direction from the paCO2 measured by capillary blood gas analysis (reference standard).

Day 1 (single study visit)
Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and Transcutaneous Carbon Dioxide (tcPCO2)
Prazo: Day 1 (single study visit)

In a subgroup of 50 participants with COPD, the average size of the difference, regardless of direction (mean absolute deviation), from the paCO2 measured by capillary blood gas analysis (reference standard) is calculated for lumetry and for transcutaneous carbon dioxide monitoring (tcPCO2). The outcome is the difference between these two averages. Unit: millimeters of mercury (mmHg).

Day 1 (single study visit)

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Number of Participants With Adverse Events, Adverse Device Effects, or Device Deficiencies
Prazo: Day 1 (single study visit)

Number of participants with at least one adverse event, adverse device effect, or device deficiency related to the study procedures, recorded during the study visit.

Day 1 (single study visit)
Cross-Validated Sensitivity of a Re-Trained lumetry COPD Screening Algorithm
Prazo: Day 1 (single study visit)

Exploratory analysis. Sensitivity of a re-trained version of the lumetry machine learning algorithm for identifying participants with chronic obstructive pulmonary disease (COPD), estimated by stratified repeated k-fold cross-validation using the study data. Reference standard: forced spirometry and documented clinical diagnosis.

Day 1 (single study visit)
Cross-Validated Specificity of a Re-Trained lumetry COPD Screening Algorithm
Prazo: Day 1 (single study visit)

Exploratory analysis. Specificity of a re-trained version of the lumetry machine learning algorithm for identifying participants without COPD, estimated by stratified repeated k-fold cross-validation using the study data. Reference standard: forced spirometry and documented clinical diagnosis.

Day 1 (single study visit)
Cross-Validated Mean Absolute Deviation of Re-Trained lumetry paCO2 Estimates From Blood Gas paCO2
Prazo: Day 1 (single study visit)

Exploratory analysis. Average size of the difference, regardless of direction (mean absolute deviation), between the arterial carbon dioxide level (paCO2) estimated by a re-trained version of the lumetry machine learning algorithm and the paCO2 measured by capillary blood gas analysis, estimated by stratified repeated k-fold cross-validation in participants with COPD. Unit: millimeters of mercury (mmHg).

Day 1 (single study visit)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Arschang Valipour, Prim. Priv. -Doz. Dr., Klinik Floridsdorf, Department of Respiratory and Critical Care Medicine

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

  • Klemm et al. Predicting arterial pCO2 using capnographic recordings - A pilot study using a novel breath analysis device. Eur Respir J. 2025; 66(Suppl 69): PA2529. doi:10.1183/13993003.congress-2025.PA2529

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2027

Conclusão do estudo (Estimado)

1 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

16 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de novembro de 2026

Primeira postagem (Real)

20 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

20 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever